Reset

Advanced Filters
11:00am - 02:00pm EDT - September 9, 2020

Wednesday
11:00am - 11:15am EDT - September 9, 2020
Clinical (and Beyond) In Use Stability Studies – Challenges, Considerations and Case Studies
Clinical in use stability studies are required for any new parenteral drug product, whether submitting the first IND/IMPD or filing the marketing authorization application. These studies are vital to our clinicians in the field as the studies determine the compatibility with common medical ancillaries, define storage conditions of the prepared product and demonstrate that our medicines are stable throughout the preparation and administration to our patients. The learning objectives for this forum are:

1. Considerations for designing phase appropriate compatibility and in-use studies
2. Microbial considerations for extemporaneous dose preparations for parenteral products
3. Analytical considerations for clinical in-use stability studies – what are the phase appropriate tests to perform
4. Analytical method challenges for low concentration in-use samples and case studies on how to overcome these challenges


Wednesday
A review of the regulatory requirements and guidance recommendations to support storage conditions of reconstituted and/or diluted drug products during IND development and for BLA approval will be presented. Microbial challenge study design and data analysis will be discussed. Case studies will be presented to illustrate how the microbial challenge data support the label instructions for storage conditions.

Wednesday
12:00pm - 12:10pm EDT - September 9, 2020

Wednesday
Antimicrobial effectiveness testing (AET) is used to confirm that preservative included in a formulation or diluent is effective at inhibiting growth of microorganisms, and AET is a requirement for multi-use drug products. This talk summarizes basic concepts of AET and discusses when testing is necessary. A case study is presented that highlights the need to understand AET variability and its relationship to preservative concentration during early development of a multi-dose program.

Wednesday
01:10pm - 01:15pm EDT - September 9, 2020

Wednesday
01:15pm - 01:55pm EDT - September 9, 2020
*Speaker Lutz Asmus has not allowed the sharing of slides or the archived recording.

Wednesday
01:55pm - 02:00pm EDT - September 9, 2020

11:00am - 02:00pm EDT - September 10, 2020
Tom Schomogy, Chair; Julie Heflin, Chair; Sarah Demmon, Speaker; Dan Boisvert, Speaker; Bhargav Patel, Speaker

Thursday
11:00am - 11:05am EDT - September 10, 2020

Thursday
Biologic products are generally unstable for storage and handling outside of refrigerated conditions and are typically not preserved. This talk examines considerations for the different types of clinical and patient use conditions such as diluent composition, drug handling and concerns with microbial growth. Examples are provided for the types of studies performed and data sets needed to justify defined periods outside of refrigerated conditions.

Thursday
11:30am - 11:55am EDT - September 10, 2020
Dan Boisvert, Speaker
Dosage Administration Instructions are required prior to clinical dosing throughout a product lifecycle. Oftentimes, multi-specific antibodies as well as traditional antibodies are evaluated at dosing ranges (protein concentrations) significantly below the analytical capacity of product specific or platform established methods. This requires coordination between clinicians, formulators, and analytical groups. The material presented provides an overview of Pfizer’s analytical approach, describing a pre-verification workflow employed to rapidly identify alternative methods. In addition, there will be a discussion of alternative methods used in DAI studies and development considerations for these studies. Finally, a case study will be discussed in which these concepts were applied successfully.

Thursday
11:55am - 12:30pm EDT - September 10, 2020
Sarah Demmon, Panelist; Dan Boisvert, Panelist

Thursday
12:30pm - 12:45pm EDT - September 10, 2020

Thursday

Clinical in use studies is key deliverable to ensure product quality and patient safety during drug administration in clinical setting. As a result of potency and/or bioavailability restrictions, many of parenteral drugs are administered intravenously and the variety of ancillary components available in the market poses many challenges. One of the key targets of intravenous administration is sterility of dose solution to ensure patient safety. To achieve the sterile administration at the use of in-line filter is deemed necessary for IV infusions. This raises many challenges such as filter adsorption and drug product compatibility. In addition, the drug product is usually further diluted to achieve the target dose concentration for administration. As a result of further dilution of drug product, diluent compatibility raises many analytical challenges by impacting sample matrix, sample concentration and column chemistry. A practical approach is shown here to overcome in-line filter adsorption challenges. Furthermore, various different sample preparation techniques and method modifications approaches are shown to overcome in-use analytical challenges.


Thursday
01:25pm - 01:45pm EDT - September 10, 2020
Julie Heflin, Chair; Bhargav Patel, Panelist

Thursday
01:45pm - 02:00pm EDT - September 10, 2020